Program
spinosad
Also written as “Spinosad”, “APT-001 topical ophthalmic ointment (spinosad)” and “DE-105 ophthalmic solution”.
Its studies are mostly in Blepharitis · Lice Infestations · Epilepsy, led by 4 companies.
Drug pageSpinosad: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ParaPROits history only | 40 open or running | phase 4since Aug 6, 2012 | Oct 15, 2007 | none ahead |
| Aperta Biosciencesits history only | 21 open or running | phase 2since Dec 3, 2024 | Dec 3, 2024 | Jan 2027phase 2 · NCT07904767 |
| Santen Pharmaceutical | 10 open or running | phase 2since Sep 30, 2009 | Sep 30, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Jul 9, 2015 | Jul 9, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Santen Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2009First study: phase 2 study in Persistent Corneal Epithelial DefectFirst studyNCT00988494 · 45 enrolled · Japan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Nicotinic acetylcholine receptor agonist”ChEMBL 37, by rule
Studies
The one study Santen Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00988494Persistent Corneal Epithelial Defect · Japan | 2 | Completed | 45 |
How it is read
Names in the registry
- “Spinosad”, 4 entries
- “APT-001 topical ophthalmic ointment (spinosad)”, 2 entries
- “DE-105 ophthalmic solution”, 2 entries
- “[18F]MNI-792 (tracer)”, 1 entry
- “spinosad”, 1 entry
Conditions, from the studies’ own filings
- Blepharitis, 2 studies
- Lice Infestations, 2 studies
- Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.